

Figure 18d. MIC Distribution among *E. coli* from Pork Chop

Antimicrobial	Year				Distribution (%) of MICs (µg/ml) <sup>4</sup>																		
	# of Isolates	% <sup>1</sup>	%R <sup>2</sup>	[95% CI] <sup>3</sup>	0.015	0.03	0.06	0.125	0.25	0.50	1	2	4	8	16	32	64	128	256	512	1024		
Aminoglycosides	Amikacin	2002 (n=184)	0.0	0.0	(0.0 - 2.0)						0.5	17.4	64.7	14.7	2.7								
		2003 (n=218)	0.0	0.0	(0.0 - 1.7)						0.5	16.5	61.5	15.6	6.0								
		2004 (n=232)	0.0	0.0	(0.0 - 1.6)						0.4	15.5	56.0	26.3	1.3	0.4							
		2005 (n=205)	0.5	0.0	(0.0 - 1.8)						1.5	11.2	62.0	19.5	5.4		0.5						
	Gentamicin	2002 (n=184)	0.0	1.1	(0.1 - 3.9)					4.9	66.3	21.2	6.0	0.5		1.1							
		2003 (n=218)	0.0	1.4	(0.3 - 4.0)					3.7	53.2	36.2	5.0	0.5		0.5	0.9						
		2004 (n=232)	0.4	1.3	(0.3 - 3.7)					10.3	57.8	26.7	3.4		0.4		1.3						
	Kanamycin	2002 (n=184)	0.5	5.4	(2.6 - 9.8)					6.8	56.1	34.1	2.0		1.0								5.4
		2003 (n=218)	0.0	8.7	(5.3 - 13.3)										92.9	1.1		0.5					8.7
		2004 (n=232)	0.0	8.2	(5.0 - 12.5)										89.9	1.4							8.2
		2005 (n=205)	0.0	7.3	(4.2 - 11.8)										89.2	2.6							5.9
	Streptomycin	2002 (n=184)	N/A	22.3	(16.5 - 29.0)												77.7	10.9					11.4
2003 (n=218)		N/A	19.7	(14.7 - 25.6)												80.3	6.9					12.8	
2004 (n=232)		N/A	21.1	(16.1 - 26.9)												78.9	8.6					12.5	
2005 (n=205)		N/A	13.2	(8.9 - 18.6)												86.8	7.3					5.9	
Aminopenicillins	Ampicillin	2002 (n=184)	1.6	13.6	(9.0 - 19.4)						1.1	30.4	47.8	5.4	1.6								13.6
		2003 (n=218)	1.4	13.3	(9.1 - 18.5)						1.8	25.7	52.8	5.0	1.4								13.3
		2004 (n=232)	0.9	15.1	(10.7 - 20.4)						12.9	44.4	25.0	1.7	0.9		0.9						14.2
		2005 (n=205)	2.4	16.1	(11.3 - 21.9)						9.3	40.5	28.3	3.4	2.4		2.0						14.1
β-Lactam/β-Lactamase Inhibitor Combinations	Amoxicillin-Clavulanic Acid	2002 (n=184)	0.5	5.4	(2.6 - 9.8)						1.6	23.9	56.0	12.5	0.5		4.4					1.1	
		2003 (n=218)	0.5	5.0	(2.5 - 8.8)						3.2	17.9	54.1	19.3	0.5		2.8					2.3	
		2004 (n=232)	0.4	5.6	(3.0 - 9.4)						4.3	27.6	46.6	15.5	0.4		4.7					0.9	
		2005 (n=205)	0.5	2.9	(1.1 - 6.3)						2.9	21.0	52.2	20.5	0.5		2.0					1.0	
Cephems	Cephalothin	2002 (n=184)	25.0	10.3	(6.3 - 15.7)						0.5	8.2	56.0		25.0		6.0					4.4	
		2003 (n=218)	39.0	11.9	(7.9 - 17.0)						0.5	6.0	42.7		39.0		6.9					5	
	Ceftiofur	2002 (n=184)	0.0	0.5	(0.0 - 3.0)			7.1	64.1	27.2	0.5	0.5			0.5								
		2003 (n=218)	0.0	0.9	(0.1 - 3.3)			5.5	53.7	38.1	1.8				0.9								
		2004 (n=232)	0.0	0.4	(0.0 - 2.4)			7.3	51.7	39.7	0.9				0.4								
		2005 (n=205)	1.0	0.5	(0.0 - 2.7)			3.4	58.0	34.6	2.0	0.5	1.0			0.5							
	Ceftriaxone	2002 (n=184)	0.0	0.0	(0.0 - 2.0)						97.8	1.1	0.5		0.5								
		2003 (n=218)	0.5	0.0	(0.0 - 1.7)						97.7	0.9	0.5		0.5								
		2004 (n=232)	0.4	0.0	(0.0 - 1.6)						97.0	1.7	0.9		0.5								
	Cefoxitin	2002 (n=184)	1.6	3.3	(1.2 - 7.0)						96.1	2.4	1.0		0.5								
		2003 (n=218)	3.2	2.3	(0.7 - 5.3)								20.1	58.2	16.9	1.6		3.3					
		2004 (n=232)	0.4	2.2	(0.7 - 5.0)								12.4	54.1	28.0	3.2		2.3					
2005 (n=205)		0.5	2.0	(0.5 - 4.9)								0.9	2.6	26.7	59.9	7.3	0.4	1.3				0.9	
Folate Pathway Inhibitors	Sulfamethoxazole	2002 (n=184)	N/A	12.5	(8.1 - 18.2)											83.2	3.26	0.5	0.54			12.5	
		2003 (n=218)	N/A	15.1	(10.7 - 20.6)											83.5	0.9	0.5				15.1	
	Sulfisoxazole	2004 (n=232)	N/A	19.4	(14.5 - 25.1)											69.8	3.0	6.9	0.4	0.4		19.4	
		2005 (n=205)	N/A	14.1	(9.7 - 19.7)											62.4	18.0	4.4	0.5	0.5		14.1	
	Trimethoprim-Sulfamethoxazole	2002 (n=184)	N/A	1.1	(0.1 - 3.9)			88.6	4.4	5.4	0.5			0.5									
Phenicol	Chloramphenicol	2002 (n=184)	2.2	1.6	(0.3 - 4.7)						0.5	31.5	64.1		2.2		1.6						
		2003 (n=218)	6.9	4.1	(1.9 - 7.7)						0.9	15.1	72.9		6.9		2.3					1.8	
		2004 (n=232)	0.9	4.3	(2.1 - 7.8)						0.9	34.1	59.9		0.9		1.3					3.0	
		2005 (n=205)	2.4	3.4	(1.4 - 6.9)						2.9	35.1	56.1		2.4		2.0					1.5	
Quinolones	Ciprofloxacin	2002 (n=184)	0.0	0.0	(0.0 - 2.0)	96.2	2.7	1.1															
		2003 (n=218)	0.0	0.0	(0.0 - 1.7)	96.3	3.2																
		2004 (n=232)	0.0	0.0	(0.0 - 1.6)	97.8	0.9	0.4	0.4	0.4													
		2005 (n=205)	0.0	0.5	(0.0 - 2.7)	90.2	4.9	1.0	2.9	0.5					0.5								
	Nalidixic Acid	2002 (n=184)	N/A	0.5	(0.0 - 3.0)						2.2	16.9	74.5	5.4	0.5		0.5						
		2003 (n=218)	N/A	0.5	(0.0 - 2.5)						2.8	44.5	50.0	2.3									0.5
		2004 (n=232)	N/A	0.0	(0.0 - 1.6)						9.9	68.5	19.4	1.3	0.9								
		2005 (n=205)	N/A	1.5	(0.3 - 4.2)						9.8	67.3	18.0	2.4	1.0		1.5						
Tetracyclines	Tetracycline	2002 (n=184)	0.5	52.7	(45.2 - 60.1)						46.7	0.5		2.2		1.6						48.9	
		2003 (n=218)	0.9	46.3	(39.6 - 53.2)						52.8	0.9		1.8		0.9						43.6	
		2004 (n=232)	2.2	56.0	(49.4 - 62.5)						41.8	2.2				6.0						50.0	
		2005 (n=205)	1.0	45.9	(38.9 - 52.9)						53.2	1.0				2.4						43.4	

<sup>1</sup> Percent of isolates with intermediate susceptibility

<sup>2</sup> Percent of isolates that were resistant

<sup>3</sup> 95% confidence intervals for percent resistant (%R) were calculated using the Clopper-Pearson exact method

<sup>4</sup> The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Vertical black bars indicate the breakpoints for susceptibility, while vertical red bars indicate the breakpoints for resistance. Numbers in the shaded area indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent the percentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available. There are no CLSI breakpoints for streptomycin